Exposure–Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP

An exposure–efficacy analysis of the phase 3 ASPECT-NP trial was performed to evaluate the relationship between plasma exposure of ceftolozane and tazobactam and efficacy endpoints (primary: 28-day all-cause mortality; key secondary: clinical cure at test-of-cure visit) in adult participants with ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Wei, Passarell, Julie, Patel, Yogesh T., Zhang, Zufei, Lin, Gina, Fiedler-Kelly, Jill, Bruno, Christopher J., Rhee, Elizabeth G., De Anda, Carisa S., Feng, Hwa-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112930/
https://www.ncbi.nlm.nih.gov/pubmed/35471040
http://dx.doi.org/10.1128/aac.01399-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9112930/
https://www.ncbi.nlm.nih.gov/pubmed/35471040
http://dx.doi.org/10.1128/aac.01399-21

Ejemplares similares